Source: American Pharmaceutical Review Gene therapies stand at the forefront of medical breakthroughs, promising revolutionary treatment possibilities. These therapies involve manipulating or modifying genes to treat or prevent diseases, presenting
Source: Patient Worthy Challenges Unique to Cell and Gene Therapies (CGTx) Clinical Trials Cell and gene therapies (CGTx) have emerged as a novel and advanced treatment modality with a one-and-done
Source: Healthcare Business Today Cell and gene therapies (CGTx) hold immense promise as transformative treatments for a wide range of diseases. However, the successful translation of these therapies from the
Source– BioProcess International The infusion of artificial intelligence (AI) technology in drug development has led to transformative solutions to age-old challenges, reshaping the trajectory from laboratory discovery to market availability.
Delays in clinical trials, worsened by the Inflation Reduction Act (IRA), are now a challenge to patient access to new therapies. Evolving complex regulatory requirements, patient recruitment issues, and logistical
Innovative technologies have revolutionized how clinical trials are conducted, catering to a diverse range of participants while ensuring patient-centricity remains a top priority. Embracing decentralized trial software, especially eCOA software
Clinical trial sponsors need reliable patient data to ensure compliance and adhere to the regional and national guidelines. While the complexities persist in clinical trials, with variations in data sets
The need for greater patient engagement isn’t a new issue today. It has persisted for decades, and the struggle to optimize it is still a priority. Even after enormous efforts,
In the bustling world of clinical research, where every discovery holds the promise of a brighter future, patient engagement and compliance stand as the guiding stars, holding eCOA software, as
Source: Telehealth and Medicine Today Clinical trials, the bedrock of medical research, are facing a pervasive challenge that threatens the very foundation of therapeutic development: high dropout rates among participants.
Source: Healthcare Business Today In the fast-evolving healthcare industry, the quest for innovative therapies is often hindered by formidable obstacles, chief among them being the protracted duration and exorbitant expenses
Source: HealthIT Answers The landscape of drug development is fraught with escalating costs and formidable challenges. Lengthy timelines, exorbitant expenses, and regulatory hurdles often impede progress, hindering the timely delivery
Jeeva Clinical Trials Inc.
